Trending...
- Naperville Police Participate in St. Patrick's Day Traffic Safety Campaign
- New partnership bringing trauma-informed libraries to vulnerable children
- Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch
Neurolixis issued a new US patent for treatment of Fragile X syndrome with NLX-101
PARK RIDGE, N.J. - illiNews -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that the United States Patent and Trademark Office (USPTO) granted a patent (US11974992B2) covering the use of NLX-101, a clinical phase drug candidate, for treatment of Fragile X syndrome (FXS). FXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on illi News
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on illi News
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on illi News
- This Creator Breaks Through - 130 Million Views and Rising
- JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams
- 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map
- JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
- U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on illi News
- New Report Reveals Surprising Trends in Ohio Airport Accidents
- Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
- WCC Kitchens and Cabinets Featured on Selling Houses Australia
- The Latest Premium Robotic Massage Chair in the US
- Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Source: Neurolixis, Inc.
Filed Under: Health
0 Comments
Latest on illi News
- Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations
- Compliant Workspace announces partnership with Blackpoint Cyber
- Michigan Homeowners Urged to Act on Rising Basement Waterproofing Needs Amid Severe Flood
- Event Solutions Enters New Era: Announces New Leadership
- Carlsbad Hotel Named Best of La Quinta Award Winner
- Scoop Social Co. Launches a New Era of Mobile Hospitality — One Truck, Two Experiences
- Record Sales Growth After Strategic Acquisitions; New Distribution Agreements for Established Premium Cigar Supplier: Green Leaf Innovations $GRLF
- R2 Copilot Addresses Critical Privacy Issues as Enterprise AI Spending and Security Incidents Rise
- Innovative Environmental Technologies Unveils New Website Featuring Free AI Tools for the Environmental Industry
- CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
- Impact Filtration Appoints Alejandro Sturniolo as Head of Sustainability to Engineer High-Performance, Water-Positive Infrastructure
- Hedge Funds Benchmark Against Tickeron AI After Platform Posts 129% Annualized Return Amid Tariff Volatility
- NAWLA Members Approve Bylaws Amendments With Strong Support
- Naperville: Annual Arbor Day Tree Sale Begins Online at 8 a.m. March 23
- 106 Years Strong: The Liberty Group Celebrates a Century-Plus of Service and Unveils a Unified Family of Companies
- Illinois Leaders Mark 15th Anniversary of State's Death Penalty Abolition
- Airport Transportation Reaches All Five Continents Through Global Transportation Partner Network
- Report: Chicago's Safety Plan Showing Promising Results in Key Neighborhoods
- Chicago: Mayor Brandon Johnson, CDOT, And Lyft Announce Extension Of $99 Divvy Membership for New Riders and Major System Expansion
- Acquisition of Israeli Defense Manufacturing Platform to Accelerate AI-Driven Autonomous Systems: VisionWave Holdings, Inc.: (N A S D A Q: VWAV)